Evaluating BI 1015550 over at least 52 weeks | Clinical Research Studies Listing

Recruiting

18 years - 99 years

All

1 Location

Brief description of study

This is a double-blind, placebo controlled study to assess the safety and efficacy of BI1015550 on patients with IPF. It is a phase 3 study and will including physical exams, a CT, questionnaires, safety lab samples, lung function testing, and ECGs.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Idiopathic Pulmonary Fibrosis,IPF
Age: 18 years - 99 years
Gender: All

Updated on 04 Aug 2024. Study ID: 852126

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Evaluating BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)

Brief description of study

Eligibility of study

Find a site

Interested in the study